1st International Conference on Chemo and BioInformatics, ICCBIKG 2021, (284-287)
AUTHOR(S) / AUTOR(I): Marija Carapic, B. Katarina Nikolic, C. Danica Agbaba
E-ADRESS / E-ADRESA: marija.carapic@alims.gov.rs, knikolic@pharmacy.bg.ac.rs , danica@pharmacy.bg.ac.rs
DOI: 10.46793/ICCBI21.284C
ABSTRACT / SAŽETAK:
KEY WORDS / KLJUČNE REČI:
REFERENCES / LITERATURA:
- Harrison, T.S.; Scott, L.J. Ziprasidone: A review of its use in schizophrenia and schizoaffective disorder . CNS Drugs, 2009, 20 (12), 1027-1052.
- Pavlovic, M.; Malesevic, M.; Nikolic, K.; Agbaba, D. Development and validation of an HPLC method for determination of ziprasidone and its impurities in pharmaceutical dosage forms. AOAC Int., 2010, 94 (3), 713-722.
- Gaussian 98 (Revision A.7), M. J. Frisch at al., Gaussian, Inc., Pittsburgh PA, 1998.
- SIMCA P+ program, Version 12.0, Umetrics AB, Umea, Sweden, May 2008, umetrics.com
- Eriksson, ; Johansson, E.; Kettaneh-Wold, N.; Trygg, J.; Wikstrom, C.; Wold, S. (Eds.) In: Multi- and Megavariate Data Analysis. Basic Principles and Applications I, 2nd ed., Umetrics Academy, Umeå, 2001, pp. 39-65.
- Nikolic K., Pavlovic M., Smoliński A., Agbaba D. The Chemometric Study and Quantitative Structure Retention Relationship modeling of Liquid Chromatography separation of Ziprasidone components. Combinatorial Chemistry & High Throughput Screening 2012, 15, 730-744.
- Čarapić M, Nikolic K, Marković B, Petković M, Pavlovic M, Agbaba. Ultra‐performance liquid chromatography tandem mass spectrometryfor the rapid, simultaneous analysis of ziprasidone and its impurities. Biomedical Chromatography. 2018;e4384. https://doi.org/10.1002/ bmc.4384